Trial Profile
A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administered alone or in conjunction with intranasal fluticasone propionate on the symptoms of rhinitis in the Vienna allergen challenge chamber.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 705498 (Primary) ; Fluticasone propionate
- Indications Allergic rhinitis
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Jun 2011 New trial record